Adhesion molecules: a new target for immunoliposome-mediated drug delivery
Publication date
1995-01-03
Authors
Bloemen, P. G.M.
Henricks, P. A.J.
van Bloois, Louis
van den Tweel, M. C.
Bloem, A. C.
Nijkamp, Frans
Crommelin, Daan
Storm, Gerrit
Editors
Advisors
Supervisors
Document Type
Letter
Metadata
Show full item recordCollections
License
No license information available
Abstract
The anti-ICAM-1 monoclonal antibody F10.2 was conjugated to liposomes to target to cells expressing the cell adhesion molecule ICAM-1. We demonstrate that F10.2 immunoliposomes bind to human bronchial epithelial cells (BEAS-2B) and human umbilical vein endothelial cells (HUVEC) in a specific, dose- and time-dependent manner. It appears that the degree of ICAM-1 expression is the limiting factor in the degree of immunoliposome binding to the cells. These results are a first step in the strategy for specific drug delivery to target sites characterised by increased expression of adhesion molecules.
Keywords
bovine serum albumine, BSA, CHOL, cholesterol, dimethylformamide, DMF, EDTA, egg-phosphatidylglycerol, Endothelium, EPG, Epithelium, ethylene diaminetetraacetic acid, FCS, fluorescein isothiocyanate-labeled goat anti-mouse mAb, foetal calf serum, GamFITC, HBS, HEPES-buffered saline, human umbilical vein endothelial cells, HUVEC, ICAM-1, IFN-γ, Immunoliposome, intercellular adhesion molecule-1, interferon-γ, mAb, mean fluorescence intensity, MFI, Monoclonal antibody, monoclonal antibody, MPB-PE, N-succinimidyl S-acetylthioacetate, N-[4-(p-maleimidophenyl)butyryl] phosphatidylethanolamine, partially hydrogenated egg l-α-phosphatidylcholine, PBS, PHEPC, phosphate-buffered saline, phospholipid, PL, SATA, TNF-α, tumor necrosis factor-α, vascular cell adhesion molecule-1, VCAM-1, Taverne, Biophysics, Structural Biology, Biochemistry, Molecular Biology, Genetics, Cell Biology
Citation
Bloemen, P G M, Henricks, P A J, van Bloois, L, van den Tweel, M C, Bloem, A C, Nijkamp, F P, Crommelin, D J A & Storm, G 1995, 'Adhesion molecules: a new target for immunoliposome-mediated drug delivery', FEBS Letters, vol. 357, no. 2, pp. 140-144. https://doi.org/10.1016/0014-5793(94)01350-A